{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-084317","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.351888+00:00","generated_at":"2026-06-08T18:37:53.469422+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nektar reports Q3 net loss $45.8M, cash $372.7M; Phase 2b atopic derm study initiated","bullets":["Net loss $45.8M ($0.24/shr) vs $59.0M y/y; non-GAAP loss $35.7M ($0.19/shr).","Revenue $24.1M, slightly up from $23.6M y/y; cash $372.7M, down from $505.0M at year-end.","Initiated Phase 2b study of rezpegaldesleukin in atopic dermatitis (Oct 2023); Phase 2b alopecia areata to start early 2024.","Clinical collaboration with CBMG to evaluate NKTR-255 in combination with TIL therapy in NSCLC.","R&D expense reduced to $24.1M (Q3) due to wind-down of bempegaldesleukin program."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-084317","json":"https://secwatch.observer/filing/0001213900-23-084317.json","markdown":"https://secwatch.observer/filing/0001213900-23-084317.md","text":"https://secwatch.observer/filing/0001213900-23-084317.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390023084317/0001213900-23-084317-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390023084317/ea187824-8k_nektarther.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T18:37:53.469422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d3551f284629444de2abc826f0f1d74c4e3a4d24","claim":"NEKTAR THERAPEUTICS reported the third quarter ended September 30, 2023 results: revenue $24.1 million, net income Net loss for the third quarter of 2023 was $45.8 million or $0.24 basic and diluted loss per share, EPS $0.24 basic and diluted loss per share.","evidence_excerpt":"least $320 million in cash and investments which provides us with a cash runway into the middle of 2026.” Summary of Financial Results Revenue in the third quarter of 2023 was $24.1 million as compared to $23.6 million in the third quarter of 2022. Revenue for the first nine months of 2023 was $66.2 million as compared to $70.0 million in the first nine months of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000121390023084317/0001213900-23-084317-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$24.1 million"},{"label":"Net income","value":"Net loss for the third quarter of 2023 was $45.8 million or $0.24 basic and diluted loss per share"},{"label":"EPS","value":"$0.24 basic and diluted loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}